Chardan Capital Remains a Buy on Femasys (FEMY)

Chardan Capital analyst Research Report) today and set a price target of $15.00. The company’s shares closed today at $2.08.

According to TipRanks, Nakae is a 4-star analyst with an average return of 7.3% and a 40.46% success rate. Nakae covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Arbutus Biopharma, and Synlogic.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Femasys with a $6.50 average price target, which is a 212.76% upside from current levels. In a report released on July 29, H.C. Wainwright also maintained a Buy rating on the stock with a $8.00 price target.

See the top stocks recommended by analysts >>

The company has a one-year high of $8.40 and a one-year low of $1.26. Currently, Femasys has an average volume of 377.9K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Femasys Inc is a biomedical company focused on transforming women’s healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. Its mission is to provide women with minimally-invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics.

Read More on FEMY:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More